OPKO Health, Inc. (0KCS.L)
USD 1.42
(0.71%)
USD 1.42
(0.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -188.86 Million USD | 42.42% |
| 2022 | -328 Million USD | -1011.86% |
| 2021 | -29.5 Million USD | -196.45% |
| 2020 | 30.58 Million USD | 109.8% |
| 2019 | -312 Million USD | -103.92% |
| 2018 | -153 Million USD | 49.88% |
| 2017 | -305.25 Million USD | -1116.14% |
| 2016 | -25.1 Million USD | 16.33% |
| 2015 | -30 Million USD | 82.53% |
| 2014 | -171.7 Million USD | -50.08% |
| 2013 | -114.4 Million USD | -293.85% |
| 2012 | -29.04 Million USD | -2164.07% |
| 2011 | -1.28 Million USD | 93.22% |
| 2010 | -18.92 Million USD | 37.15% |
| 2009 | -30.11 Million USD | 24.4% |
| 2008 | -39.83 Million USD | 85.16% |
| 2007 | -268.4 Million USD | -41320.52% |
| 2006 | -648 Thousand USD | -248.39% |
| 2005 | -186 Thousand USD | 90.34% |
| 2004 | -1.92 Million USD | 66.75% |
| 2003 | -5.79 Million USD | 44.07% |
| 2002 | -10.35 Million USD | -17.91% |
| 2001 | -8.78 Million USD | -22.61% |
| 2000 | -7.16 Million USD | -64.45% |
| 1999 | -4.35 Million USD | -61.37% |
| 1998 | -2.7 Million USD | 18.18% |
| 1997 | -3.3 Million USD | -13.79% |
| 1996 | -2.9 Million USD | -7.41% |
| 1995 | -2.7 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -81.83 Million USD | -23.05% |
| 2024 Q2 | -10.3 Million USD | 87.41% |
| 2023 Q1 | -18.2 Million USD | 78.64% |
| 2023 Q2 | -19.64 Million USD | -7.91% |
| 2023 Q3 | -84.5 Million USD | -330.24% |
| 2023 FY | -188.86 Million USD | 42.42% |
| 2023 Q4 | -66.5 Million USD | 21.29% |
| 2022 Q2 | -101.65 Million USD | -83.54% |
| 2022 Q1 | -55.38 Million USD | 24.95% |
| 2022 FY | -328 Million USD | -1011.86% |
| 2022 Q3 | -86.04 Million USD | 15.35% |
| 2022 Q4 | -85.2 Million USD | 0.99% |
| 2021 FY | -29.5 Million USD | -196.45% |
| 2021 Q1 | 31.07 Million USD | -3.78% |
| 2021 Q4 | -73.8 Million USD | -356.79% |
| 2021 Q3 | 28.73 Million USD | 277.55% |
| 2021 Q2 | -16.18 Million USD | -152.08% |
| 2020 Q4 | 32.3 Million USD | 36.19% |
| 2020 Q1 | -59.13 Million USD | 47.39% |
| 2020 Q3 | 23.71 Million USD | -29.63% |
| 2020 FY | 30.58 Million USD | 109.8% |
| 2020 Q2 | 33.7 Million USD | 157.0% |
| 2019 Q4 | -112.4 Million USD | -81.27% |
| 2019 Q1 | -80.8 Million USD | -6.18% |
| 2019 Q2 | -59.8 Million USD | 25.98% |
| 2019 Q3 | -62 Million USD | -3.68% |
| 2019 FY | -312 Million USD | -103.92% |
| 2018 Q3 | -27.65 Million USD | -345.98% |
| 2018 Q4 | -76.1 Million USD | -175.18% |
| 2018 Q1 | -43.1 Million USD | 79.85% |
| 2018 FY | -153 Million USD | 49.88% |
| 2018 Q2 | -6.2 Million USD | 85.61% |
| 2017 Q4 | -213.9 Million USD | -360.57% |
| 2017 Q3 | -46.44 Million USD | -164.96% |
| 2017 Q1 | -30.99 Million USD | -126.24% |
| 2017 Q2 | -17.52 Million USD | 43.45% |
| 2017 FY | -305.25 Million USD | -1116.14% |
| 2016 FY | -25.1 Million USD | 16.33% |
| 2016 Q4 | -13.7 Million USD | 8.67% |
| 2016 Q3 | -15 Million USD | -196.57% |
| 2016 Q2 | 15.53 Million USD | 229.68% |
| 2016 Q1 | -11.97 Million USD | -848.63% |
| 2015 Q4 | 1.6 Million USD | -98.75% |
| 2015 Q1 | -117.11 Million USD | -120.97% |
| 2015 Q2 | -42.76 Million USD | 63.48% |
| 2015 Q3 | 128.24 Million USD | 399.88% |
| 2015 FY | -30 Million USD | 82.53% |
| 2014 Q4 | -53 Million USD | -8.9% |
| 2014 Q2 | -25.48 Million USD | 42.81% |
| 2014 FY | -171.7 Million USD | -50.08% |
| 2014 Q1 | -44.55 Million USD | -165.18% |
| 2014 Q3 | -48.66 Million USD | -91.01% |
| 2013 Q2 | -3.39 Million USD | 90.08% |
| 2013 FY | -114.4 Million USD | -293.85% |
| 2013 Q4 | -16.8 Million USD | 72.0% |
| 2013 Q3 | -59.99 Million USD | -1667.77% |
| 2013 Q1 | -34.21 Million USD | -6143.61% |
| 2012 Q3 | -9.64 Million USD | 5.85% |
| 2012 Q2 | -10.24 Million USD | -18.98% |
| 2012 Q4 | -548 Thousand USD | 94.32% |
| 2012 Q1 | -8.61 Million USD | -146.79% |
| 2012 FY | -29.04 Million USD | -2164.07% |
| 2011 Q3 | -8.23 Million USD | -43.33% |
| 2011 FY | -1.28 Million USD | 93.22% |
| 2011 Q4 | 18.4 Million USD | 323.45% |
| 2011 Q2 | -5.74 Million USD | -0.74% |
| 2011 Q1 | -5.7 Million USD | -747.55% |
| 2010 FY | -18.92 Million USD | 37.15% |
| 2010 Q2 | -6.21 Million USD | -32.69% |
| 2010 Q4 | -673 Thousand USD | 90.85% |
| 2010 Q1 | -4.68 Million USD | 48.45% |
| 2010 Q3 | -7.35 Million USD | -18.33% |
| 2009 Q2 | -5.67 Million USD | 36.91% |
| 2009 Q1 | -8.99 Million USD | 7.7% |
| 2009 FY | -30.11 Million USD | 24.4% |
| 2009 Q4 | -9.08 Million USD | -43.0% |
| 2009 Q3 | -6.35 Million USD | -11.95% |
| 2008 Q4 | -9.74 Million USD | -17.06% |
| 2008 FY | -39.83 Million USD | 85.16% |
| 2008 Q1 | -10.88 Million USD | -21.19% |
| 2008 Q2 | -10.87 Million USD | 0.01% |
| 2008 Q3 | -8.32 Million USD | 23.46% |
| 2007 Q1 | -249.93 Million USD | -67817.12% |
| 2007 Q4 | -8.97 Million USD | -706.21% |
| 2007 Q3 | 1.48 Million USD | 113.5% |
| 2007 Q2 | -10.97 Million USD | 95.61% |
| 2007 FY | -268.4 Million USD | -41320.52% |
| 2006 Q2 | -68 Thousand USD | -58.14% |
| 2006 Q3 | -168 Thousand USD | -147.06% |
| 2006 Q4 | -368 Thousand USD | -119.05% |
| 2006 FY | -648 Thousand USD | -248.39% |
| 2006 Q1 | -43 Thousand USD | 87.05% |
| 2005 Q2 | -434 Thousand USD | -49.66% |
| 2005 FY | -186 Thousand USD | 90.34% |
| 2005 Q4 | -332 Thousand USD | -138.12% |
| 2005 Q3 | 871 Thousand USD | 300.69% |
| 2005 Q1 | -290 Thousand USD | -0.69% |
| 2004 Q4 | -288 Thousand USD | 21.74% |
| 2004 FY | -1.92 Million USD | 66.75% |
| 2004 Q2 | -531 Thousand USD | 28.15% |
| 2004 Q3 | -368 Thousand USD | 30.7% |
| 2004 Q1 | -739 Thousand USD | 50.27% |
| 2003 Q2 | -1.79 Million USD | -81.86% |
| 2003 Q1 | -987 Thousand USD | 75.46% |
| 2003 Q3 | -1.52 Million USD | 15.04% |
| 2003 FY | -5.79 Million USD | 44.07% |
| 2003 Q4 | -1.48 Million USD | 2.56% |
| 2002 Q1 | -1.76 Million USD | -1.38% |
| 2002 Q2 | -1.88 Million USD | -6.56% |
| 2002 FY | -10.35 Million USD | -17.91% |
| 2002 Q3 | -2.68 Million USD | -42.28% |
| 2002 Q4 | -4.02 Million USD | -49.96% |
| 2001 Q3 | -2.75 Million USD | 6.68% |
| 2001 Q4 | -1.74 Million USD | 36.59% |
| 2001 FY | -8.78 Million USD | -22.61% |
| 2001 Q1 | -1.34 Million USD | 10.25% |
| 2001 Q2 | -2.94 Million USD | -120.07% |
| 2000 FY | -7.16 Million USD | -64.45% |
| 2000 Q1 | -2.41 Million USD | -66.03% |
| 2000 Q4 | -1.49 Million USD | 23.75% |
| 2000 Q2 | -1.29 Million USD | 46.47% |
| 2000 Q3 | -1.95 Million USD | -51.2% |
| 1999 Q3 | -1 Million USD | -25.0% |
| 1999 FY | -4.35 Million USD | -61.37% |
| 1999 Q4 | -1.45 Million USD | -45.7% |
| 1999 Q2 | -800 Thousand USD | 27.27% |
| 1999 Q1 | -1.1 Million USD | -37.5% |
| 1998 Q4 | -800 Thousand USD | 20.0% |
| 1998 FY | -2.7 Million USD | 18.18% |
| 1998 Q1 | -800 Thousand USD | 0.0% |
| 1998 Q2 | -200 Thousand USD | 75.0% |
| 1998 Q3 | -1 Million USD | -400.0% |
| 1997 FY | -3.3 Million USD | -13.79% |
| 1997 Q1 | -700 Thousand USD | 12.5% |
| 1997 Q2 | -800 Thousand USD | -14.29% |
| 1997 Q3 | -900 Thousand USD | -12.5% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1996 FY | -2.9 Million USD | -7.41% |
| 1996 Q1 | -700 Thousand USD | 0.0% |
| 1996 Q2 | -700 Thousand USD | 0.0% |
| 1996 Q3 | -800 Thousand USD | -14.29% |
| 1996 Q4 | -800 Thousand USD | 0.0% |
| 1995 FY | -2.7 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 103.15% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2856.065% |
| Illumina, Inc. | -1.16 Billion USD | 83.733% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 113.907% |
| Biogen Inc. | 1.16 Billion USD | 116.266% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 57.467% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 123.944% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 64.763% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 14451.292% |
| Waters Corporation | 642.23 Million USD | 129.407% |
| Perrigo Company plc | -12.7 Million USD | -1387.11% |
| uniQure N.V. | -308.47 Million USD | 38.776% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 46.359% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -24.593% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 31.603% |
| bluebird bio, Inc. | -211.91 Million USD | 10.877% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -59.361% |
| Imunon, Inc. | -19.51 Million USD | -867.785% |
| Myriad Genetics, Inc. | -112 Million USD | -68.628% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 175.636% |
| Nektar Therapeutics | -276.05 Million USD | 31.585% |
| Editas Medicine, Inc. | -153.21 Million USD | -23.263% |
| Verastem, Inc. | -87.36 Million USD | -116.172% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.813% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -323.428% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -70.826% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -373.816% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 212.657% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 26.749% |
| Evolus, Inc. | -61.68 Million USD | -206.173% |
| Adicet Bio, Inc. | -142.65 Million USD | -32.389% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -113.45% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 104.777% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 9.742% |
| FibroGen, Inc. | -284.23 Million USD | 33.553% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 115.231% |
| Homology Medicines, Inc. | -53.74 Million USD | -251.419% |
| Geron Corporation | -184.12 Million USD | -2.572% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 57.1% |
| Exelixis, Inc. | 207.76 Million USD | 190.902% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -119.877% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -297.564% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 60.751% |
| Zoetis Inc. | 2.34 Billion USD | 108.057% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 21.056% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -248.533% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 105.218% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -347.553% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 48.438% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 277.938% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 167.069% |
| Blueprint Medicines Corporation | -506.98 Million USD | 62.748% |
| Insmed Incorporated | -749.56 Million USD | 74.804% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1590.396% |
| Incyte Corporation | 597.59 Million USD | 131.604% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 75.166% |